Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06555952 · ClinicalTrials.gov registry record · NA
MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors
A NA study of Hypertension and PreDiabetes, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06555952: Recruiting NA study of Hypertension and PreDiabetes, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
NCT06555952 is a NA study of Hypertension and PreDiabetes that is actively recruiting participants, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 80 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06555952, a NA study of Hypertension and PreDiabetes, is actively recruiting participants, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Inflammation and stressors can interfere with the function of the lining of blood vessels and insulin activity, therefore, investigators are aiming to see how the Grape seed Extract (GSE) called MegaNatural BP can help with limiting the effects of these factors. This research will study the effects of taking 150mg of MegaNatural BP GSE per day on blood pressure levels along with influences on heart health through assessing the function of the blood vessel lining and levels of inflammation.
Primary Outcome
After 6 weeks of 150mg GSE MegaNatural BP per day the base level blood pressure should change
Conditions Studied
Interventions
- OTHER Placebo Capsule
- DIETARY_SUPPLEMENT MegaNatural-BP SR 150Mg Tablet
Study Locations (1)
Illinois
- Clinical Nutrition Research Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06555952 shows while recruiting
NCT06555952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo Capsule is the first listed.
NCT06555952 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06555952 about?
NCT06555952 is a clinical study titled "MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors". Inflammation and stressors can interfere with the function of the lining of blood vessels and insulin activity, therefore, investigators are aiming to see how the Grape seed Extract (GSE) called MegaNatural BP can help with limiting the effects of these factors. This research will study the effects ...
What is the current status of trial NCT06555952?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-08-08. Estimated completion is 2026-12-31.
What conditions does trial NCT06555952 study?
This clinical trial studies the following conditions: Hypertension, PreDiabetes.
What interventions are being tested in trial NCT06555952?
The interventions under investigation include: Placebo Capsule (OTHER), MegaNatural-BP SR 150Mg Tablet (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06555952?
This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06555952 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06555952's enrollment target sits among peer trials
80 316th of 470 higher than 150 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
RECRUITING · NA
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Early Time-Restricted Eating in Older Adults With Hypertension
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI